Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Current Assets (2021 - 2025)

Historic Current Assets for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $922.0 million.

  • Indivior Pharmaceuticals' Current Assets changed N/A to $922.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $922.0 million, marking a year-over-year change of. This contributed to the annual value of $827.0 million for FY2024, which is 3420.84% down from last year.
  • Indivior Pharmaceuticals' Current Assets amounted to $922.0 million in Q3 2025.
  • Over the past 5 years, Indivior Pharmaceuticals' Current Assets peaked at $1.4 billion during Q4 2021, and registered a low of $827.0 million during Q4 2024.
  • Moreover, its 5-year median value for Current Assets was $951.0 million (2025), whereas its average is $1.1 billion.
  • In the last 5 years, Indivior Pharmaceuticals' Current Assets fell by 15.89% in 2023 and then crashed by 3420.84% in 2024.
  • Indivior Pharmaceuticals' Current Assets (Quarter) stood at $1.4 billion in 2021, then decreased by 12.81% to $1.3 billion in 2022, then decreased by 0.16% to $1.3 billion in 2023, then crashed by 34.21% to $827.0 million in 2024, then rose by 11.49% to $922.0 million in 2025.
  • Its Current Assets stands at $922.0 million for Q3 2025, versus $951.0 million for Q2 2025 and $883.0 million for Q1 2025.